TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01451853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 Low Dose
Description: Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy~Arms: Low Dose~Other Names:~200 mg Ebselen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 Middle Dose
Description: Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 High Dose
Description: Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
Study: NCT01526538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: 50 mg d-cycloserine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: placebo
Study: NCT00919464

Intervention type: DEVICE
Group type: OTHER
Intervention: Pressure monitoring device
Description: monitoring device inserted to measure thigh compartment pressures

Intervention type: DEVICE
Group type: OTHER
Intervention: Compartmental fracture pressure monitoring

Intervention type: DEVICE
Group type: OTHER
Intervention: This small project is designed to be a non-randomized, investigational prospective trial of compartment pressures in the thigh following femoral fracture
Study: NCT03143400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius BL 3123
Description: Two classic forms will be tested (powder and pill). An innovative galenic form (pill with retarded release), developed to enhance intestinal viability and probiotic efficacy, will also be tested.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius BL 3123
Description: Two classic forms will be tested (powder and pill). An innovative galenic form (pill with retarded release), developed to enhance intestinal viability and probiotic efficacy, will also be tested.
Study: NCT04858100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical excision of the lesion
Description: The surgical removal of the lesion, performed within 3 months from the final diagnosis, will follow these steps:~* local anesthesia~* excision of the lesion with surgical blade or laser, according to the clinical case, paying attention to having at least 2 mm-free margins~* silk or resorbable suture for wound closure~The patient will be recall after 14 days for assessing the wound healing and after 30 days for providing and explaining him the histopahtological exam.~The patient will receive a 3-6 month follow-up according to the clinical and histopathological case.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait and see approach
Description: The patient will receive a 3-6 month follow-up according to the clinical and histopathological case, with periodical incisional biopsy every 4 control visit.~In case of OSCC onset during the first 3 months after the final diagnosis, the patient will be excluded since the oral cancer occurence will be considered as a misdiagnosis, more than a true malignat progression.
Study: NCT03937453

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI/MRCP
Description: An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed at baseline. Further imaging upon recommendation by study committee

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI/MRCP
Description: An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed at baseline. Further imaging upon recommendation by study committee
Study: NCT02532764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-010
Description: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT03621748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake Anesthesia Protocol
Description: Awake is defined as the patient being awake with electrical brain stimulation mapping during the critical portions of the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-awake Anesthesia Protocol
Description: Non-awake is general anesthesia as per convention with intubation.
Study: NCT00825708

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: 42 2 sec trains of 20HZ rTMS in 100% MT

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: shamTMS
Description: sham TMS session
Study: NCT00593281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: Add Hylenex to SC injection of Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylenex
Description: Add Hylenex to SC injection of Morphine
Study: NCT03852706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LORETA
Description: Twenty sessions of neurofeedback training using LORETA in combination with z-scores.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment-as-usual

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment-as-usual
Study: NCT02842697

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVPG measurement
Description: HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTA
Description: Three-dimensional hepatic vein-portal vein model constructed with CTA images

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Portal vein velocity measured by Doppler ultrasound
Study: NCT01520051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 3 monthly intravenous infusions of 750 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 monthly intravenous infusions with saline
Study: NCT05471674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg on Day 1 of each 2-weekly cycle for 3 doses

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Description: Hepatectomy will be performed approximately 2 weeks after the 3rd dose of nivolumab
Study: NCT02788422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video discharge instructions
Description: Online video containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: One page paper handout containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
Study: NCT03399526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat (ZK 245186, BAY 86-5319)
Description: 0.1% (1 mg/g) of the active ingredient mapracorat plus excipients as ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednicarbate 0.25% ointment
Description: 0.25% (2.5 mg/g) of the active ingredient prednicarbate as ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol 0.05% ointment
Description: 0.05% (0.5 mg/g) of the active ingredient clobetasol as ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriene 0.005% ointment
Description: 0.005% (0.05 mg/g) of the active ingredient calcipotriene as ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment
Description: 0.005% (0.05 mg/g) of the active ingredient calcipotriene/0.05% (0.5 mg/g) of the active ingredient betamethasone dipropionate as ointment
Study: NCT03561883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3718
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-dose PPIs QD
Description: background therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard-dose PPIs QD
Description: background therapy
Study: NCT03103100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine
Description: 10 mL of 1% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: 10 mL of 0.25% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus Lidocaine
Description: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
Study: NCT02276677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Single dose, intranasal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, intranasal
Study: NCT04835922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal Nerve Block
Description: : Following PCNL Intercostal nerve block will be given at 11th and 12th Intercostal space on the side of surgery with 20cc of 0.25% bupivacaine under fluoroscopy guidance in prone position lateral to mid scapular line by Urologists. The 23 G spinal needle tip will be used and located above the innermost intercostal muscle. The needle tip will be located above the innermost intercostal muscle. In the next step, following negative aspiration for blood, 20 ml of 0.25% bupivacaine will be injected into the intercostal space between innermost intercostal muscle and pleura below 11th, and 12th ribs (10 ml each)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peritract Infiltration
Description: At the end of PCNL a single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position).
Study: NCT02470507

Intervention type: OTHER
Intervention: AKI
Description: development of immune dysregulation and rise in inflammatory markers and activation of immune cells

Intervention type: OTHER
Intervention: AKI
Description: development of immune dysregulation and rise in inflammatory markers and activation of immune cells

Intervention type: OTHER
Intervention: AKI
Description: development of immune dysregulation and rise in inflammatory markers and activation of immune cells

Intervention type: OTHER
Intervention: AKI
Description: development of immune dysregulation and rise in inflammatory markers and activation of immune cells
Study: NCT01686841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study: NCT00093925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicardipine
Study: NCT03009448

Intervention type: OTHER
Intervention: Interview
Description: Each subject will be interviewed using a semi constructed interview.
Study: NCT03619252

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with pneumococcal conjugate vaccine (PCV13)
Description: Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Antibacterial Prophylaxis
Description: Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
Study: NCT02060006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5mg daily for 8 weeks
Description: Meloxicam 7.5mg daily for 8 weeks
Study: NCT00928954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Description: increasing to 1200 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine
Description: increasing to 40 mg/day
Study: NCT01255475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine/amlodipine
Description: Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo
Study: NCT01346852

Intervention type: DRUG
Intervention: Asthma treatment with an asthma-related medication and at least one asthma controller medication
Description: participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.

Intervention type: DRUG
Intervention: Asthma treatment with an asthma-related medication and at least one asthma controller medication
Description: participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
Study: NCT02473211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daclatasvir 60mg tablet administered once daily
Study: NCT02042846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SportWelding Fiji Anchor
Study: NCT02524990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based follow-up with SQPT
Description: Participants will be followed-up at home. They will receive an SQPT to perform at home two weeks after enrollment, and a scheduled follow-up phone call by study providers to determine the outcome of the procedure.
Study: NCT04304963

Intervention type: OTHER
Intervention: NO intervention - observational study
Description: NO intervention - observational study

Intervention type: OTHER
Intervention: NO intervention - observational study
Description: NO intervention - observational study

Intervention type: OTHER
Intervention: NO intervention - observational study
Description: NO intervention - observational study
Study: NCT04607239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: * A weekly telephone call by the CRA for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~* A monthly call by the attending physician for treatment titration and side effects check.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual Care without Telemonitoring
Description: * Attending the follow up visits after inclusion at Day 90 (D-90) \& Day 180 (D-180) for face to face consultation with the attending physician.~* Usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check.
Study: NCT00041509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-424323
Description: 500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-424323
Description: 500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo, oral, BID for 28 days
Study: NCT04122430

Intervention type: OTHER
Intervention: Review of Health Information
Study: NCT01134523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin, CTX, Paclitaxel
Description: Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin, Paclitaxel
Description: Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
Study: NCT03832179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex
Description: Ozurdex
Study: NCT03288766

Intervention type: PROCEDURE
Intervention: PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software
Description: The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.
Study: NCT02475083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Rehabilitation with virtual reality, using Football games, Boxe, Bambolê and Tennis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional
Description: Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.
Study: NCT01840371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional sedation
Description: Propofol Meperidine : 25 mg IV just before procedure~* IV bolus of 1 mg/kg for sedation induction,~* Infusion of 60 mcg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental sedation
Description: Fentanyl~* IV bolus of 1 µg/kg for sedation induction~* Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol~* IV bolus of 0.4 mg/kg for sedation induction~* Infusion of 30 µg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate depth of sedation
Study: NCT02324465

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision Video Laryngoscope
Description: Intubation via King Vision Video Laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope Video Laryngoscope
Description: Intubation via Glidescope Video Laryngoscope
Study: NCT02456948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 6 weeks 200mg/day Minocycline add-on

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 weeks Placebo add-on
Study: NCT03160677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target < 130 mm Hg
Description: Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 130 mm Hg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systolic blood pressure target < 185 mm Hg
Description: Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 185 mm Hg
Study: NCT00414531

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: 20 to 80 mg per day
Study: NCT02356471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications Fitbit Zip (portable pedometer device)
Description: Use pedometer to monitor physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03411005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolic availability of lysine in sorghum
Description: Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from sorghum and 1 level from sorghum with lentils.
Study: NCT02698800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue blocking (BB) lenses
Description: Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Clear lenses
Description: Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
Study: NCT03219398

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoperitoneum pressure
Description: Subjects were set to 8- 10 mmHg pressure during laparoscopic surgery; Subjects were set to 12-14 mmHg pressure during laparoscopic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoperitoneum pressure
Description: Subjects were set to 8- 10 mmHg pressure during laparoscopic surgery; Subjects were set to 12-14 mmHg pressure during laparoscopic surgery
Study: NCT01512043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing control
Description: Practice of device guided breathing control twice a day for four weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing control
Description: Practice of device guided breathing control twice a day for four weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Breathing control
Description: Practice of device guided breathing control twice a day for four weeks.
Study: NCT01755858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01902680

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal brachytherapy
Description: Focal brachytherapy with permanent I125 localized implant.